Dr. Sewanti Limaye is a highly accomplished physician and the Director of Medical & Precision Oncology at Sir H. N. Reliance Foundation Hospital. She is a trailblazer in the field, having established the Precision Oncology clinic, the first of its kind in the country to be led by a medical oncologist. Under her leadership, Oncology Clinical and Translational research at the center has reached new heights. Dr. Limaye brings with her a wealth of experience from renowned institutions such as Columbia University Medical Center-New York Presbyterian Hospital and the Dana Farber Cancer Institute/Brigham and Women's Hospital. Her expertise lies in treating various solid tumors, including breast, lung, head and neck, gastrointestinal, genitourinary, and gynecological cancers. With her medical degree from Jawahar Lal Nehru Medical College, residency in Internal Medicine from New York University, and fellowship in Hematology and Medical Oncology from Albert Einstein University, Dr. Limaye is well-versed in providing comprehensive and specialized care. She holds a Masters in Patient-Oriented Research (Cancer Genomics and Biostatistics) from Columbia University's Mailman School of Public Health. Dr. Limaye's commitment to research is evident through her collaborations with esteemed institutions such as Memorial Sloan Kettering Cancer Center, Columbia University Medical Center, and the National Cancer Institute, USA. She has led national and international trials and has served on Data Safety Monitoring Boards. Her outstanding contributions to clinical research have been recognized with prestigious awards, including the John-Flynn Young Investigator Award, Rose and Jack Horowitz Award for patient care, and the Medical Oncology Research Excellence Award from ASCO. Passionate about the development of precision protocols in cancer care and the advancement of novel therapeutics in solid tumors, Dr. Limaye envisions bringing excellence in Cancer Care, Precision Oncology, and Cancer Research to Sir H. N. Reliance Foundation Hospital. Her dedication to improving patient outcomes and her pursuit of groundbreaking research make her a valued leader in the field of oncology.